Since March this year, the University of Oxford, UK, and the Ifakara Health Institute, Tanzania, are testing a novel human rabies vaccine to be used in a single dose regimen in a Phase Ib/II trial in Tanzania. It is based on the ChAdOx2 vector, a weakened version of a common cold virus (adenovirus) similar to the technology used successfully in the Oxford-AstraZeneca COVID-19 vaccine.

Read more here: https://www.ox.ac.uk/news/2022-03-04-rabies-vaccine-candidate-begins-human-trials-tanzania